CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Curtana is developing a novel cancer treatment targeting gliomas by inhibiting the Olig2 transcription factor. Their compound, CT-179, shows promise in killing cancer stem cells and improving survival rates in pre-clinical studies, aiming to advance towards clinical trials.
Over 45,000 people die each year in Europe – and 255,000 worldwide – from cancers of the brain and central nervous system.
Gliomas are the biggest killer, accounting for a third of all diagnoses and 80% of primary malignant brain tumours.
Among these glioblastoma is the most common, most aggressive and deadliest.
Standard of care treatment offers little hope for patients diagnosed with gliomas: there is no cure, the median survival is 14.6 months and the 2-year survival rate is 13.5%.
Convention…
CURTANA PHARMA LTD
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
